A hallmark of MAFLD is the formation of IL-17A-mediated type 3 inflammation, which is a driving force behind the pathogenesis of NASH and HCC (8, 13, 50–54). This evidence concerns the gene IL17A and metabolic dysfunction-associated steatohepatitis.